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Abstract: A nano-flow high-resolution screening platform, featuring a parallel chip-based 
microfluidic bioassay and mass spectrometry coupled to nano-liquid chromatography, was 
applied to screen animal venoms for nicotinic acetylcholine receptor like (nAChR) affinity 
by using the acetylcholine binding protein, a mimic of the nAChR. The potential of this 
microfluidic platform is demonstrated by profiling the Conus textile venom proteome, 
OPEN ACCESS 
Biology 2014, 3 140 
 
 
consisting of over 1,000 peptides. Within one analysis (<90 min, 500 ng venom injected), 
ligands are detected and identified. To show applicability for non-peptides, small molecular 
ligands such as steroidal ligands were identified in skin secretions from two toad species 
(Bufo alvarius and Bufo marinus). Bioactives from the toad samples were subsequently 
isolated by MS-guided fractionation. The fractions analyzed by NMR and a radioligand 
binding assay with α7-nAChR confirmed the identity and bioactivity of several new ligands. 
Keywords: on-line microfluidics; nano-liquid chromatography-mass spectrometry  
(nano-LC-MS); Lymnaea stagnalis acetylcholine binding protein (Ls-AChBP); Conus textile; 
Bufo alvarius; Bufo marinus 
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1. Introduction 
Besides being promising pharmacological tools, bioactive compounds from “natural sources” are 
considered of interest to the pharmaceutical industry as potential medicines [1]. Compounds from 
natural sources comprise an array of molecules, which have evolved to target specific biological tasks 
and aim at, e.g., avoidance of predation, immobilizing a prey, or preventing a prey’s reproduction.  
A challenge of modern drug discovery is to identify these compounds for affinity towards a 
biochemical process or a specific protein target, to isolate them and to develop such compounds into 
innovative drugs. The first step is the selection of a natural source, which could be an extract used for 
(traditional) medicinal purposes. Other sources rich in different biologically active compounds are 
animal venoms, which contain toxins, either to catch prey or to evade predation. 
Cone snails, such as Conus textile, are predatory sea snails with venom containing more than a thousand 
conopeptides, which are small peptides with 12 to 35 amino acids and some disulfide bridges [2]. Many of 
these conopeptides target specific ion channels in the peripheral nervous system and are involved in 
the transmission of pain stimuli [3,4] often with high specificity and affinity, such as the nicotinic 
acetylcholine receptor nAChR [5–7], which therefore may be potential biopharmaceuticals. This is 
reflected by the recent FDA approval of the conopeptide-derived drug under the name Ziconotide 
(Prialt), which blocks a neuronal N-type voltage-gated calcium channel in the treatment of neuropathic 
pain [7,8]. The α9α10-type nAChR bioactive conopeptide ACV1 (from Metabolic Pharmaceuticals 
Limited, Melbourne, Australia), involved in pain relief, reached clinical trials, but was abandoned due to 
efficacy lack in humans [9]. Another conopeptide-based drug candidate, xen2174 (from Xenome Ltd., 
Brisbane, Australia), increases norepinephrine levels in the spinal cord. An inherent advantage of 
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conopeptide analysis is that identification is relatively straightforward as it can be accomplished with 
MS2 peptide sequencing [10–13] (after reduction). 
Toad skin excretions comprise a complex cocktail of small peptides, tryptamine derivatives (with 
masses between 100 and 400 Da) and steroidal compounds (with masses between 400 and 800 Da), 
and might be a natural source for bioactive compounds [14]. In contrast to conopeptides, they are 
expected to pass the blood brain barrier more easily. During evolution, toads produced the tryptamine 
derivatives from serotonin, which has been the archetype “scaffold” [15]. These compounds, being 
excreted from glands in the skin of these toads, serve to deter animals, function as anti-predation 
toxins, and are known to cause convulsion, hallucinogenic effects and (even) death [16]. Toad skin 
excretions from the Cane toad skin (Bufo marinus) and the Colorado River toad skin (Bufo alvarius) 
may also exhibit AChBP affinity. 
As the compounds in natural extracts are present in complex mixtures, the screening of these 
extracts for bioaffinity and identification of the bioactives needs to be optimally combined. 
Commonly, separation is the first step in natural extract screening after which biochemical assays on 
collected fractions are applied to screen for bioaffinity. Typically, “hits” are validated biochemically 
and their structure is elucidated by mass spectrometry (MS) and nuclear magnetic resonance 
spectroscopy (NMR), after iterative purification rounds with orthogonal separations. This traditional 
approach is laborious and requires relatively large amounts of sample [5,17–19]. A specific challenge of 
natural extract screening is the accurate matching of bioactives with their chemical structure [20–24]. 
Traditionally, bioassays are performed after low-resolution fractionation of the extract. Besides being 
laborious, this process is often only capable of identifying a small portion of the bioactives present [25], 
and closely eluting bioactives are not screened individually. 
New screening approaches for natural extracts, e.g., affinity-selection MS (AS-MS) [26], 
ultrafiltration MS [27] and high-resolution screening (HRS) [28–32], implement integrated liquid 
chromatographic (LC) separation and LC-MS. AS-MS techniques measure binding between a protein 
and its potential ligands by separating the protein-ligand complexes from the non-binding mixture 
components. Identification of the ligands is done subsequently with MS or MS-MS, whereas HRS 
techniques apply biochemical assays coupled on-line to LC-MS. 
To screen for bioactive compounds that act on the membrane-bound nAChRs, the soluble homolog 
acetylcholine binding protein (AChBP) can be used [33–36]. Recently, a HRS system, featuring an  
on-line fluorescence enhancement biochemical assay, for AChBP screening was developed [37]. The 
assay format was subsequently miniaturized in order to enable screening of venoms of which only 
limited amounts are available for analysis [38]. The miniaturized format was successfully applied for 
profiling of neurotoxic snake venoms [39]. An advantage of this “on-line” HRS technique lies in the 
ability to directly pinpoint ligands, even when the compounds in the mixture are poorly separated, 
which is often the case when screening complex venom samples. 
Here, we combine HRS, featuring nano-LC separation, on-line miniaturized biochemical assaying 
and parallel MS analysis for rapid ligand identification, to MS-guided purification to enable full 
structure elucidation by, e.g., NMR or advanced MS technologies, and biological assaying of the 
purified ligands towards the human α7-nAChR using a radioligand binding assay (RBA). Using this 
screening approach, we readily identified AChBP ligands in cone snail venom (Conus textile) and in 
natural extracts from Cane toad skin (Bufo marinus) and the Colorado River toad (Bufo alvarius). 
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2. Experimental 
2.1. Chemical and Biological Reagents 
Ls-AChBP (from the snail species Lymnaea stagnalis) was expressed from Baculovirus using the 
pFastbac I vector in Sf9 insect cells and purified from the medium, as described by Celie et al. [35]. 
Human neuroblastoma cells (SH-SY5Y) expressing human R7 nAChRs were obtained from Christian 
Fuhrer (Department of Neurochemistry, Brain Research Institute, University of Zurich, Zurich, 
Switzerland). The fluorescent tracer ligand DAHBA, (E)-3-(3-(4-diethylamino-2-hydroxybenzylidene)-
3,4,5,6-tetrahydropyridin-2-yl)pyridine, was synthesized in house [37]. Human neuroblastoma cells 
(SH-SY5Y) expressing human α7-nAChR were washed with PBS, collected as a pellet and stored at 
−80 °C until further use. 3H-Methyllycaconitine (3H-MLA) was from American Radiolabeled 
Chemicals Inc. (St. Louis, MO, USA). KCl, DL-dithiothreitol (DTT), guanidine-HCl, NaCl, trizma 
base, HCl, Tween 20, [Met5]-enkephalin and human angiotensin I, and Bufo marinus and Bufo alvarius 
extracts were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). KH2PO4, Na2HPO4 and 
NH4HCO3 were obtained from Riedel-de-Haën (Seelze, Germany). I-Nicotine (99.0%) was purchased 
from Janssen Chimica (Beerse, Belgium). Enzyme linked immunosorbent assay (ELISA) blocking 
reagent (ELISA-BR) was purchased from Hoffmann-La-Roche (Mannheim, Germany). Mca-Lys-Pro-
Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 was from Bachem (Bubendorf, Switzerland). Methanol-d4 was 
purchased from Cambridge Isotopes Laboratories, Inc. (Buchem B.V., Apeldoorn, The Netherlands). 
ULC/MS grade trifluoroacetic acid (TFA; 99.95%), formic acid (FA; 99.95%) methanol (MeOH; 
99.98%) and acetonitrile (ACN; 99.97%) were purchased from Biosolve (Valkenswaard, The 
Netherlands). HPLC grade water was produced using a Milli-Q purification system from Millipore 
(Amsterdam, The Netherlands). 
2.2. Instrumentation 
2.2.1. Microfluidic Confocal Fluorescence Detection System 
The screening platform consisted of a nano-LC unit with a post-column split to an MS and a 
microfluidic chip acting as biochemical reactor, where the LC flow and a bioassay solution were 
mixed and incubated, and a microfluidic LED based laser-induced fluorescence (LIF) detector as 
described in detail in Heus et al. [39]. 
2.2.2. Nano-LC and Solvent Delivery System 
The Ultimate nano-LC system with a Famos autosampler was from LC Packings (Amsterdam, The 
Netherlands). The gradient system was operated at 400 nL/min. Mobile phase solvent A consisted of 
water/ACN 95:5 and 0.05% FA and solvent B of water/ACN 5:95 and 0.05% FA for Conus textile 
venom analysis. The toad extracts were analyzed with solvent A consisting of water and 0.1% TFA 
and solvent B of ACN and 0.1% TFA. Sample volumes of <500 nL were injected into the analytical 
capillary column (150 mm × 75 µm internal diameter (i.d.)) packed in-house with Aqua C18 particles 
(particle size 3 µm, 200 Å pore diameter; Phenomenex, Torrance, CA, USA). For Conus textile venom 
analysis, a 70 min gradient elution was applied running five min isocratic at 5% solvent B, then rising 
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to 60% solvent B in 65 minutes. For Bufo alvarius and Bufo marinus analysis, a 70 min gradient 
elution was applied running five min isocratic at 1% solvent B, then rising to 60% solvent B in 65 min. 
2.2.3. Microfluidic Chip 
The microfluidic chip and chip holder (type 4515), produced by Micronit Microfluidics, (Enschede, 
The Netherlands), was described in detail elsewhere [38]. One inlet was used to connect the nano-LC 
carrier flow; the other inlet to a Model 980532 syringe pump (Harvard Apparatus, Holliston, MA, USA) 
to infuse the AChBP and tracer ligand DAHBA at a flow rate of 5 µL/min, as described previously [37,38]. 
2.2.4. Microfluidic LED Based LIF Detector 
The flow cell of the detector consisted of a 150 μm i.d. extended light path “bubble cell” with  
50 µm i.d. connecting capillaries (G1600 64232, Agilent Technologies, Amstelveen, The Netherlands). 
This bubble cell served as the actual flow-through detector cell. Light from a high-intensity LED 
passed a 465 nm single band pass filter, was collimated by a lens, reflected by a dichroic mirror under 
90° and focused into the centre of the bubble cell by a 20× quartz microscope objective. Emitted light 
passed the same dichroic mirror, a focusing lens, and a 520 nm single band pass filter, after which it 
was detected by photomultiplier tube. A detailed description of this detector can be found in [38]. 
2.2.5. Nano-LC-MS 
A Shimadzu (‘s-Hertogenbosch, The Netherlands) ion-trap-time-of-flight (IT-TOF) hybrid mass 
spectrometer equipped with a Picoview nano-electrospray ionization (ESI) source from New Objective 
(Woburn, MA, USA) was operated in positive-ion mode. A 40 mm × 180 µm outer diameter × 30 µm i.d. 
stainless-steel emitter was used as the spray needle (ES522, Proxeon/Thermo Scientific, Waltham, 
MA, USA). The spray needle was connected to the nano-LC system via a 1,000 mm × 10 µm i.d. bare 
fused-silica capillary by a low void volume connector (type P 720, Upchurch Scientific, Oak Harbor, 
WA, USA) which was integrated in the nano-ESI source. The temperature of the heating block and 
curved desolvation line were set to 200 °C. The interface voltage was set at 1.7 kV, resulting in a 
current of ~32 µA. 
2.2.6. MS-Guided Fractionation 
For purification, normal bore LC was performed using a 100 mm × 4.6 mm Symmetry Shield 
column at a flow rate of 0.5 mL/min. A Gilson 234 was used for sample injection (50 µL). The mobile 
phases used were the same as in nano-LC with the following gradient: 25 min at 2% B; 25 min linear 
increase to 95% B; five min at 95% B. By means of a post-column Y-split, 90% of the eluent was 
directed through a Shimadzu SPD-20A UV detector (220 nm, Shimadzu Crop., Kyoto, Japan) to a 
Gilson 234 fraction collector. Collected fractions were freeze-dried utilizing a centrifugal evaporator at 
room temperature. To the remaining 10% of the eluent, an additional flow of 50%/50% H2O/MeOH 
with 0.1% FA at 250 µL/min was mixed via a Shimadzu LC-10a pump to obtain favorable ESI flow 
rates and solvent composition. MS detection was done using ESI in the positive mode with a Q-TOF II 
mass spectrometer (Micromass, Manchester, UK). A 398 K source temperature, 573 K desolvation 
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temperature, 250 L/h desolvation gas flow, 60 L/h cone gas flow, 17 psi gas cell pressure (i.e., 20 V 
collision voltage for optimum transfer through collision cell), 3,500 V capillary voltage, and a cone 
voltage of 30 V were used. The mass range was m/z 50 to 2,000. The data acquisition parameters were 
1.0 s spectrum−1 in MS profile mode and 0.1 s delay time. Nitrogen (purity 5.0; Praxair, Oevel, 
Belgium) and argon (purity 5.0; Praxair, Oevel, Belgium) were used as desolvation/cone gas and 
collision gas, respectively. 
2.2.7. Off-Line NMR 
NMR spectra were recorded on a Bruker Avance III spectrometer equipped with a five mm Cryo 
Probe CPTXI with z-axis gradients and automatic tuning and matching accessory (Bruker Biospin, 
Rheinstetten, Germany). The spectrometer was operated via Bruker TopSpin 2.1 software, running 
under CentOS. Data was processed using TopSpin 2.1 running under Linux. The resonance frequency 
for 1H NMR was 599.76 MHz and for 13C 150.82 MHz. All spectra were recorded in methanol-d4 at 
298 K. Standard Bruker parameter settings—with the pulse sequences indicated in brackets according 
to the Bruker nomenclature—were used for recording of 1H (zgpr), 1H-1H COSY (cosygpprqf),  
1H-1H TOCSY (mlevphpr), 1H-13C HSQC (hsqcetgpsi) and 1H-13C HMBC (hmbcpgndqf) NMR 
spectra. Presaturation of the residual water resonance was performed prior to the 1H-1D and 1H-2D 
NMR experiments. All 2D NMR experiments were recorded with 2K data points in the direct 
dimension and 128 data points in the indirect dimension. The spectra were processed using zero filling 
such that data matrices of 2 K × 1 K were obtained. The spectra were calibrated against the residual 
solvent signal of methanol-d4; δ 1H 3.31 ppm, δ 13C 49.0 ppm. 
2.3. Biochemical Assays and Samples 
2.3.1. Biochemical Assay 
Fresh solutions of 5 nM Ls-AChBP and 15 nM DAHBA were made every day by dissolving in a 
bioassay solution containing 1 mM KH2PO4, 3 mM Na2HPO4, 0.16 mM NaCl, 20 mM trizma 
base/HCl at Ph 7.5 and 400 µg/mL ELISA BR. The bioassay solution was kept in a 2.5 mL syringe 
(type 1002LTN, Hamilton, Bonaduz, Switzerland) at 4 °C. The on-line bioassay itself was performed 
at 22 °C [38]. 
2.3.2. Radioligand Binding Assay 
RBAs for human α7-nAChR were performed as reported previously [34,40]. α7-Receptor expressing 
SH-SY5Y cells cells were harvested, washed with PBS and washed three times with ice-cold PBS  
by centrifugation at 4 °C. Aliquoted cell pellets were stored at −80 °C. Frozen cell pellets were 
dissolved in ice-cold PBS, homogenized and sonicated immediately before use and added to the assay. 
The final volume of binding buffer suspension with nAChR-rich membranes from SH-SY5Y cells was 
100 µL. The buffer was a 1.4 mM KH2PO4, 4.3 mM Na2HPO4, 137 mM NaCl, 2.7 mM KCl, 20 mM 
Trizma base, 0.05% Tween 20 buffer at pH 7.4. As radioligand, 3H-MLA (KD = 1.81 nM) was used at 
a concentration of 2.5 nM. The SH-SY5Y homogenate was incubated with 10−3–10−1 M of ligand. 
Crude Bufo alvarius skin extracts were dissolved at 300 µg of crude mixture per 100 µL assay buffer, for 
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an (arbitrary) compound concentration of 10−3 M, assuming skin extract compounds average at 300 Dalton. 
After an incubation period of 1.5 h under continuous shaking, bound radioligand was collected on 
0.3% polyethyleneimine-pretreated Uniﬁlter-96 GF/C ﬁlters (Perkin Elmer, Waltham, USA) and 
washed using ice-cold washing buffer (4 °C) consisting of 50 mM Tris-HCl buffer at pH 7.5. After the 
ﬁlters were dried, scintillation ﬂuid (MicroScint, Perkin Elmer) was added after which radioactivity 
was measured in a Wallac 1450 MicroBeta liquid scintillation counter (Perkin Elmer). To determine 
non-specific binding, radioligand saturation experiments were performed with nicotine. The concentration 
of nicotine used was 1 mM. Binding assay data was analyzed using Prism 5.0 (Graphpad Software, Inc., 
San Diego, California, USA). 
2.3.3. Conus textile Venom 
Lyophilized venom sample from Conus textile was acquired as described by Dutertre et al. [41].  
1 mg of lyophilized venom was dissolved in water/MeOH 95:5% at a concentration of 5 mg/mL and 
subsequently centrifuged at 13,400 rpm for 10 min to remove particulate matter. Aliquots of these 
samples were stored at −20 °C until use. Before analysis, nicotine was added as internal standard at an 
end concentration of 40 µM. 
Venom peptide cysteine bridges were reduced by adding 2 µL of the 5 mg/mL venom mixture to  
18 µL reduction solution, which was then allowed to react at 50 °C for 45 min. The reduction solution 
contained 1 M DTT and 2 M guanidine-HCl, buffered at pH 8.5 by 50 mM NH4HCO3. The reduced 
venom was then analyzed by nano-LC-MS. During the LC-MS analysis of the reduced venom mixture, 
the nano-LC unit remained hyphenated to the bioaffinity screening setup. This served as an indication 
whether the reduced peptide(s) remained bioactive. Full MS spectra were acquired between m/z 150 
and 3,000. Data-dependent MS2 data were obtained with a precursor ion isolation width of 3.0 atomic 
mass units and product ions between m/z 150 and 2,000. In a subsequent analytical run, MS2 data was 
targeted for the reduced α-TxIA peptide at m/z 831.360 (from ions obtained between m/z 150 and 
1,800 in the ion trap). MS2 product-ion m/z values were compared with theoretical α-TxIA peptide 
fragments as calculated by the University of California, San Francisco’s (UCSF’s) protein prospector. 
Theoretical fragment calculation was based on the α-TxIA sequence as published by Dutertre et al. [41]. 
2.3.4. Toad Skin Excretion Extracts 
Lyophilized skin secretion samples from Bufo alvarius and Bufo marinus were dissolved in 
water/ACN 99:1 and 0.1% TFA at a concentration of 10 mg/mL and subsequently centrifuged at 
13,400 rpm for 10 min. Aliquots of these samples were stored at −20 °C until further use. Before 
analysis, three reference peptides at an end concentration of 2 µM each were added. The resulting 
solutions were directly injected in duplicate onto the nano-LC system for parallel bioaffinity screening 
and MS identification. Samples were re-analyzed at lower or higher concentrations whenever 
necessary. The three reference peptides were used to align MS data between different runs, whenever 
necessary. The three reference peptides were [Met5] enkephalin, human angiotensin I, and Mca-Lys-
Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2, which were detected at m/z 627.146, 648.848, and 
611.307, respectively. 
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3. Results and Discussion 
This work describes the application of an efficient analytical HRS platform for the bioaffinity 
profiling and subsequent MS-guided purification of compounds from natural sources. Previously, we 
showed its applicability to the bioaffinity profiling of neurotoxic snake peptides (between 60 and 90 
amino acids) for Ls-AChBP binding [39]. Here, profiling is demonstrated for small peptides and small 
bioactive molecules in neurotoxic cone snail venoms and in extracts of toad skin excretions, 
respectively. In this extended workflow, the toxins identified with the miniaturized HRS platform were 
subsequently isolated by “normal-bore” LC using MS-guided fractionation. Thereafter, isolated small 
molecular ligands were structurally elucidated by NMR and biologically assessed using an RBA for 
assessing human α7-nAChR binding. 
The miniaturized analytical screening setup was used as described by Heus et al. [39]. Half of the 
400 nL/min effluent from the nano-LC is split to the nano- ESI interface. The other half is hyphenated 
to the microfluidic chip where it is continuously mixed with the bioassay solution, which is infused at 
5 µL/min by a syringe pump. The chip outlet is connected to the confocal LED-induced fluorescence 
detector, which monitors the eluting toxins for bioaffinity after in-flow and in-chip incubation. The 
biochemical assay is based on fluorescence enhancement in which the tracer ligand DAHBA shows 
increased fluorescence when bound to the AChBP. Eluting ligands, when competing with DABHA for 
Ls-AChBP binding, are observed as a negative peak. Identified bioactives may then be subsequently 
purified by normal-bore LC-MS, guided by the accurate mass of the ligands, for further 
pharmacological studies on human nAChRs. This subsequent MS-guided purification setup is shown 
in Figure 1. 
Figure 1. Schematic diagram of the MS-guided purification. Venom is injected for 
analysis (1). After (large bore) LC (2), a split allows eluting toxin constituents to collection 
vials for NMR analysis (3) with help of a 1:9 post-LC split and to go to ESI-MS for 
monitoring of toxin mass (4). 
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3.1. Method Evaluation for Cone Snail Venoms 
To evaluate the applicability and performance of the miniaturized methodology for the screening of 
bioactive peptides in snail venom, a dilution series of the venom was first analyzed in order to assess 
sensitivity, repeatability, and correlation of peak shapes observed in MS and the biochemical assay, as well 
as the (post-column) band broadening. This was done by injecting 0.1, 0.5 and 2.5 μg of Conus textile 
venom in a 500 nL sample (Supporting Information, Figure S1). In Conus textile venom, one AChBP 
ligand was found. The analysis of 2.5 μg venom showed some peak broadening, but not as extreme as 
was observed for some high-affinity snake toxins [39]. Previously, we demonstrated that a purified 
cone snail (Conus imperialis) peptide was detected with high sensitivity and with not much peak 
broadening in the bioassay. Some tailing in the bioassay is observed, which is common for on-line 
bioassays as the response is sigmoidal (see Heus et al. [39]). Here, we found a similar peak shape in 
the bioassay of the crude Conus textile venom analysis for the bioactive peptide. From parallel MS 
analysis, the correlated m/z of the bioactive peptide was rapidly identified, as shown in Figure 2.  
The peak in the extracted ion chromatogram (EIC) of the ion with m/z 829.347 correlated to the 
bioassay peak of the cone snail peptide. The estimated limit of detection of the bioactive peptide was 
around 0.5 μg venom in 0.5 μL injected. 
3.2. Cone Snail Toxin Screening 
Correlation of the MS data with the bioaffinity data (Figure 2) conveniently identified the binding 
conotoxin peptide amongst the over 1,000 peptides present in the cone snail venom [2]. The 2+-ion 
with m/z 829.347 (Figure 2; insert) matches with the known α7-nAChr ligand α-TxIA with 
(GCCSRPPCIANNPDLC, amidated C-terminal, theoretical m/z of [M+2H]2+ is 829.338, mass error 
+9 mDa), found by Dutertre et al. [41]. For further confirmation of the peptide identity, the whole 
venom was reduced with DTT and then analyzed in data-dependent MS2 analysis (Figure 3). The ion 
with m/z 829.347 was no longer found, but a 2+-ion with m/z 831.359 (mass error +6 mDa) emerged, 
i.e., the original peptide m/z + 2, which corresponds to an accurate peptide mass of 1,661.694 Da. 
Figure 3 shows the MS2 spectrum of this peptide in the venom extract and in the inserts the total ion 
current (TIC) chromatogram (A) and the MS1 spectrum of the relevant chromatographic peak (B). The 
m/z + 2 after reduction in the 2+-ion indicates the reduction of two cysteine bridges, which is in line 
with the peptide α-TxIA. The partial sequence of the peptide can be derived from the MS2 spectrum, as 
shown in Figure 3. In fact, this experiment shows a strategy for confirmation of the presence of 
disulfide bridges of a found bioactive peptide, based on reduction of all disulfide bridges: after 
reduction by DTT, the bioactive peak should disappear, and another peak should appear somewhere in 
the chromatogram, featuring an m/z shift corresponding to the number of disulfide bridges present. 
Sequencing of this reduced peptide can be achieved by MS2. As we confidently identified the peptide 
as being the α-TxIA peptide based on accurate mass, the presence of the two expected disulfide 
bridges and the (partial) sequence information from the MS2 data (see Figure 3), and because the 
peptide was already characterized by Dutertre et al.[41], we decided not to proceed with subsequent 
purification in this case. 
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Figure 2. Typical result of a crude snail venom analysis where 2.5 μg of crude Conus textile 
venom was injected in a 500 nL sample. High resolution MS1 analysis and on-line bioassay 
data were obtained in parallel. This analytical run obtained one ligand, identified as  
α-TxIA by the high resolution MS1 analysis. 40 µM nicotine functioned as an alignment 
compound between the MS and the bioassay trace (the split nicotine peak is due to the 
addition of 5% MeOH to the sample; the chromatographic run started at 5% ACN).  
The binding signal in the bioassay trace aligned with the doubly charged ion with  
m/z 829.347 (mass spectrum is shown in the insert), which corresponds to a monoisotopic 
mass of 1,656.678 Da. 
 
3.3. Screening of Toad Skin Excretions 
For the screening of toad skin excretion extracts, no nicotine was added to the samples as it could 
interfere with the detection of small-molecule ligands. In the lyophilized skin excretions (5 μg) of the 
Bufo marinus and Bufo alvarius, a total of six AChBP ligands were found. Both species exhibited 
almost identical binding profiles, as shown in Figure 4 and Figure S2 in the supporting information for  
Bufo marinus and Bufo alvarius, respectively. The ligands found in Bufo marinus were fractionated by 
normal-bore LC-MS. The advantage of using MS-guided purification is that with MS analysis we can 
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plot EICs of m/z values seen in the area of fraction collection. Plotting the EICs can show the peak 
purity of our collected fractions, while UV detection does not give information about the purity of the 
eluting peaks. Once peak purity is known, one can subsequently revert to UV based fractionation as 
the data obtained from LC-UV-MS can be translated to LC-UV for further easy, cost effective and 
convenient LC-UV based purification. The ligands found in Bufo marinus were fractionated by 
normal-bore LC. For the fraction collection 50 µL 10 mg/mL Bufo marinus skin extract sample was 
injected to the LC. The isolated compounds were then analyzed in a RBA to assess real α7-nAChR 
binding. Again, AChBP proved to be a valid homologue of the α7-nAChR binding pocket, as  
the identified ligands showed binding affinity to the α7-nAChR in radioligand displacement assay.  
NMR data were acquired for additional structural elucidation/confirmation. 
Figure 3. Data-dependent MS2 spectrum analysis of the reduced α-TxIA peptide. 
Fragments that can be attributed to α-TxIA are marked. The doubly charged peptide with 
m/z 831.360 results in a peptide mass of 1,661.689 Da, which is in good agreement with 
the previously published mass of 1,661.67 Da of α-TxIA. The inserts show the total ion 
current chromatogram and the extracted ion current of m/z 831.354 (insert A) and the MS1 
spectrum of the corresponding chromatographic fraction (insert B). 
 
In MS analysis, the first bioactive compound (at a retention time of 8.5 min) showed an ion with 
m/z 303.168, consistent with a most-likely formula of C12H23N4O5+ (mass error −1.9 mDa). Although 
an information-rich MS2 spectrum was obtained, we did not succeed in interpreting the data to retrieve 
the identity of this compound (Supporting Information, Figure S3). Structure proposals of the second 
(minor) bioactive (10.0 min; m/z 205.098; C11H13N2O2+; +0.8 mDa) and third bioactive compound 
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(10.5 min; m/z 219.112; C12H15N2O2+; −0.7 mDa) could only be made upon interpretation of the MS2 
spectra (Figures S4 and S5 in supporting information). Both compounds, assuming the structure 
proposals are correct, have not been described in relation to this toad venom. Unfortunately, for these 
three minor bioactivity peaks, too many co-eluting compounds were present to obtain sufficiently pure 
fractions for unambiguous NMR analysis. 
Figure 4. An analysis of a 500 nL sample containing 5 µg Bufo marinus lyophilized skin 
secretion extract obtained six binding signals. 
 
The fourth bioactive compound (m/z 203.118; C12H15N2O+; mass error within 1 mDa), co-eluting 
with compound 3, was identified as dehydrobufotenin (Figure 5), a well-documented bufotoxin [42]. 
In MS2, the subsequent losses of two methyl radicals (CH3●) confirmed the dimethyl-substituted quaternary 
ammonium character of this compound (Supporting Information, Figure S6). NMR analysis confirmed 
these findings (see Section 3.4 and Supporting Information, Figure S7A–C). 
The fifth bioaffinity signal at 58.0 min correlated to a compound that was identified as marinobufagin 
(m/z 401.234; C24H33O5+, mass error +5 mDa; in some cases appearing as a proton-bound dimer 
[2M+H]+ with m/z 801.460), also reported by Gao et al. [43] (Figure 5). The MS2 spectrum 
(Supporting Information, Figure S8) is in agreement with data reported earlier [14,44]. NMR data 
supported these findings (see Section 3.4. and Supporting Information, Figure S9A,B). 
The sixth bioaffinity signal at 62.0 min correlated to a compound with m/z 713.414 (C38H57N4O9+, 
mass error +2 mDa). The molecular formula is consistent with arginine-suberoyl marinobufagenin, 
reported by Yoshika et al. [45] (Figure 5). The MS2 spectrum shows the expected loss of the 
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marinobufagenin part of the molecule with charge retention on the arginine-suberoyl part (Supporting 
Information, Figure S10), consistent with data reported by Yoshika et al. [45]. Subsequent losses 
involve typical small molecule losses (H2O, CO, NH3, and CH2N2) expected for the arginine-suberoyl 
part. A definitive confirmation of the structure by NMR was not possible because of the low  
signal-to-noise ratio of the NMR spectrum (see Section 3.4). 
Figure 5. Structures of the identified bioactives from Bufo marinus skin secretion extract, 
confirmed by both MSn and NMR. 
 
3.4. NMR Data on Toad Fractions 
Compounds analyzed by NMR are numbered below according to the description in the results and 
discussion based on the nano-LC elution order. 
Compound 4: (m/z 203.118) The proton spectrum of compound 4 exhibited three characteristic 
dehydrobufotenin signals in the aromatic region at δ 7.33 ppm (1H, d, J = 8.6 Hz), δ 7.15 ppm (1H, s) 
and δ 6.83 ppm (1H, d, J = 8.6 Hz). In the aliphatic region, two methylene signals at δ 4.06 ppm (2H, t, 
5.9 Hz) and δ 3.33 ppm (2H, t, 5.9 Hz) and two methyl signals both at δ 3.73 ppm (6H, s) were 
observed, confirming the structure to be dehydrobufotenin. Carbon assignments were corroborated by 
1H,13C-HSQC and 1H,13C-HMBC experiments (Supporting Information, Figure S7A–C). 
Compound 5: (m/z 801.460; proton-bound dimer) compound 5 has been assigned as marinobufogenin. 
The essential signals in 1H-1D and 1H-2D spectra are the α-pyrone signals at δ 7.90 ppm (1H, dd,  
J = 9.7, 2.4 Hz), δ 7.45 ppm (1H, dd, J = 2.4, 1.0 Hz) and δ 6.26 ppm (1H, dd, J = 9.7, 1.0 Hz), the 
epoxy signal 15 CH at δ 1H 3.61 ppm (1H, d, J = 8.5 Hz) and two methyl signals at δ 0.79 ppm (3H, s) 
ppm and δ 0.97 ppm (3H, s). The specific carbon resonances were observed in 1H,13C-HSQC or 
1H,13C-HMBC at δ 60.7, 75.7 ppm for the epoxy and δ 124.3, 164.6 ppm for the α-pyrone. Almost all 
of the steroidal signals are doubled as also seen in compound 6. Compound 5 and 6 were most 
probably purified as two co-eluting fractions as compound 6 was found in compound 5, and vice versa. 
As this did not interfere with the NMR elucidation and NMR was performed to assist the MS 
measurements, further purification attempts were not done. Although the resonance of 18CH3 were 
also doubled, most of the extra signals originated from a modification around C3/C5 as could be 
observed in 2D TOCSY, HSQC and HMBC data (Supporting Information, Figure S9A,B). 
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Compound 6: (m/z 713.414) Only the steroidal specific shifts for 18CH3 and 19CH3 at resp. δ 0.79 ppm 
and δ 1.00 ppm were observed for compound 6. Those chemical shifts are close to those of 
marinobufagenin (compound 5) but slightly modified, probably in the A or B-ring. The signals of the 
low content compound 6 are doubled in a 60/40-ratio. The major signals are in the aromatic region 
equal to the signals of compound 5. In addition, the 1H chemical shift at 0.78 ppm corresponding to 
18CH3 is identical to the one in compound 5. The signal of H15 was not observed at the same shift. 
The chemical shift of 19CH3 at 1.00 ppm is slightly higher than the observed 19CH3 shift in 
marinobufagenin at 0.97 ppm. This might indicate that the suberoyl is added at position 3. 
Nevertheless, the compound is marinobufagin-like and modified in the A and B-ring indicating  
di-suberoyl marinobufagin, which is in accordance with the MS data. 
3.5. Bufo alvarius Bioaffinity Assessment 
Our current HRS approach aims at rapid assessment of binders. Therefore, the (usually low) amount 
of each bioactive compound isolated can only be roughly estimated and a quantitative assessment of 
relative binding potencies cannot be made. We estimate that between 0.05 and 0.5 mg compound was 
collected, which is sufficient for NMR analysis and an initial assessment of binding to nAChR in a 
RBA. First, the crude Bufo alvarius skin excretion sample was analyzed by a traditional RBA for  
α7-nAChR to assess binding potency of included compounds. This showed 50% binding at a 
concentration of ~3 mg/mL. Serial dilutions were prepared for the purified fractions 1, 2, 4, 5 and 6. 
For all fractions, RBA show binding to nAChR, except for fraction 6 (at the current total amount of 
compound isolated and re-dissolved). 
4. Conclusions 
This work demonstrates that the developed miniaturized on-line HRS system was able to identify  
a bioactive peptide in the Conus textile with AChBP affinity amongst >1,000 (small) peptides.  
The current methodology was able to identify the bioactive conotoxin within two rapid analytical runs 
(60 min each). It does so robustly and is able to use minute amounts of venom (2.5 μg). Therefore, the 
HRS platform enables efficient screening for bioactives in natural extracts which are available only in 
low sample amounts, e.g., spider and scorpion venoms. To show that this platform is also applicable to 
screen non-peptide small compounds (molecular weight of 200 to 1,000 Da), skin secretions from the 
Colorado River toad (Bufo alvarius) and Cane toad (Bufo marinus) were analyzed. The results 
demonstrated several tryptamine-like and steroidal ligands, which, to our knowledge, have as of yet 
never been correlated with AChBP (and/or nAChR) affinity. By extending our workflow with a rapid 
analytical purification, NMR analysis, and rescreening in either the miniaturized screening system or a 
conventional RBA, we were able to isolate bioactive toxins from natural extracts in a straightforward 
and sample conserving way for initial and rapid chemical and biochemical assessment. 
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